What Is Compounded Semaglutide?
Compounded semaglutide is a version of the active ingredient in Wegovy and Ozempic produced by compounding pharmacies rather than by the manufacturer, Novo Nordisk. Compounding pharmacies are permitted to produce copies of drugs that appear on the FDA's official drug shortage list — and semaglutide was on that list for several years due to extraordinary demand.
The appeal was straightforward: price. Brand-name Wegovy and Ozempic cost over $1,000 per month without insurance. Compounded semaglutide was available through telehealth platforms and compounding pharmacies for $150–$400 per month. For seniors without drug coverage, the savings were significant.
Why Medicare Does Not Cover Compounded Versions
Medicare Part D — and the new GLP-1 Bridge — covers only FDA-approved, brand-name prescription drugs. Compounded semaglutide and compounded tirzepatide (the active ingredient in Zepbound and Mounjaro) are not FDA-approved products. They are custom-produced by individual pharmacies under a different regulatory framework.
Because compounded drugs are not FDA-approved, they cannot appear on any Medicare Part D formulary. This means:
- You cannot apply compounded semaglutide costs toward your Part D deductible
- You cannot apply them toward your annual out-of-pocket maximum
- The $50 Bridge price does not apply — you pay entirely out of pocket
There is no workaround. If you use a compounded version, you are outside Medicare coverage entirely for that prescription.
The Shortage Loophole Is Closing
The legal basis for most compounded semaglutide production was the drug shortage designation. The FDA officially removed semaglutide from the shortage list in early 2025, which ended the legal authorization for compounding pharmacies to produce copies of Wegovy and Ozempic.
Following that decision, the FDA sent enforcement letters to compounding pharmacies and telehealth platforms producing semaglutide copies. Many have stopped. Some continue while litigation plays out, but the legal ground is increasingly narrow.
Tirzepatide (the ingredient in Zepbound) remains in a more contested status. Some compounding pharmacies continue producing it citing shortage designations; the FDA has disputed this. The legal situation is actively evolving as of mid-2026.
If you are currently using a compounded GLP-1 medication, check directly with your pharmacy about its current legal status in your state.
How the Bridge Changes the Math
Before the Bridge, the price comparison looked like this:
| Option | Monthly cost |
|---|---|
| Compounded semaglutide (telehealth) | ~$200–$400 |
| Brand-name Wegovy (no insurance) | ~$1,300+ |
| Brand-name Wegovy (Bridge, eligible seniors) | $50 |
The $900+ gap between compounded and brand-name was the entire reason compounded alternatives existed for Medicare-age seniors. The Bridge largely eliminates that gap for eligible members. At $50 per month, brand-name Wegovy is less expensive than most compounded alternatives were charging.
For seniors who qualify for the Bridge, continuing with a compounded version no longer makes financial sense — and carries legal and clinical risks that brand-name does not.
Clinical Considerations
Beyond the coverage question, there are real differences between compounded and FDA-approved versions:
Dosing consistency. Brand-name Wegovy comes in a pre-filled injection pen calibrated to a precise dose. Compounded vials typically require drawing the medication with a syringe — introducing room for measurement error.
Inactive ingredients. Some compounding pharmacies add ingredients not present in the brand-name formula, such as Vitamin B12, cyanocobalamin, or other supplements. These additions have not been studied in clinical trials alongside semaglutide. Their interactions and effects at scale are unknown.
Sterility standards. FDA-approved manufacturing facilities operate under strict good manufacturing practice (GMP) regulations. Compounding pharmacy standards vary and are subject to less frequent federal oversight.
No clinical trial data. The safety and efficacy evidence for semaglutide — the landmark STEP trial series — was generated using the brand-name formulation at specific doses, not compounded versions.
None of this means compounded semaglutide is necessarily unsafe. But it does mean the risk profile is less well understood than with the brand-name drug.
What to Do If You Are Currently Using Compounded Semaglutide
- Check your Bridge eligibility — use the 2-minute eligibility quiz to find out if you qualify for the $50 Bridge
- Talk to your doctor about transitioning to brand-name Wegovy or Zepbound
- Confirm your Part D plan — make sure you are enrolled in a Part D or MA-PD plan, which is required to access the Bridge
- Review the prior authorization process — your prescriber submits a PA directly to CMS; the Medicare GLP-1 guide walks through exactly how this works
The transition from compounded to brand-name is medically straightforward. Your doctor adjusts the prescription and initiates the Bridge prior authorization. Most patients report minimal disruption when switching.
Track Your Progress
Already on a GLP-1? Use the free CairnSpace tracker to log your daily protein, hydration, symptoms, and weight — built specifically for people on GLP-1 medications. No sign-up fees, no ads.